The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis

Multiple Sclerosis

Volumn 11, Issue 2, 2005, Pages 175-181

  Patten, Scott B ^a   Francis, Gordon ^b   Metz, Luanne M ^a   Lopez Bresnahan, Maria ^b   Chang, Peter ^b,c   Curtin, Francois ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b EMD SERONO INC   (United States)

^c Serono Inc   (Switzerland)

Author keywords

Adverse effects; Chemically induced depressive disorder; Depressive symptoms; Interferons; Mental depression; Multiple sclerosis; Post marketing; Product surveillance; Psychiatric symptom rating scales

Indexed keywords

BETA1A INTERFERON; PLACEBO;

ARTICLE; ATYPICAL DEPRESSION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; RATING SCALE; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SUICIDE ATTEMPT; SYMPTOMATOLOGY;

ADJUVANTS, IMMUNOLOGIC; DATABASES, FACTUAL; DEPRESSIVE DISORDER; HUMANS; INTERFERON-BETA; MENTAL STATUS SCHEDULE; MULTIPLE SCLEROSIS; PRODUCT SURVEILLANCE, POSTMARKETING; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SUICIDE;

EID: 15544371181     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458505ms1144oa     Document Type: Article

References (26)

1. Sadovnick AD, Remick RA, Allen J, Swartz E, Yee IML, Eisen K et al. Depression and multiple sclerosis. Neurology 1996; 46: 628-32.
2. Joffe RT, Lippert GP, Gray TA, Sawa G, Horvath Z. Mood disorder and multiple sclerosis. Arch Neurol 1967; 44: 376-78.
3. Minden SL, Orav J, Reich P. Depression in multiple sclerosis. Gen Hosp Psychiatry 1987; 9: 426-34.
4. Schiffer RB, Caine ED, Bamford KA, Levy S. Depressive episodes in patients with multiple sclerosis. Am J Psychiatry 1983; 140: 1498-500.
5. Patten SB, Metz LM, Reimer MA. Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Mult Scler 2000; 6: 115-20.
6. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). J Am Med Assoc 2003; 289: 3095-105.
7. Patten SB, Beck CA, Williams JVA, Barbui C, Metz LM. Major depression in multiple sclerosis. Neurology 2003; 61: 1524-27.
8. Patten SB, Barbui C. Drug-induced depression: a systematic review to inform clinical practice. Psychother Psychosom 2004; 73: 207-215.
9. The IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-85.
10. Goeb JL, Cailleau A, Laine P, Etcharry-Bouyx F, Maugin D, Duverger P et al. Acute delirium, delusion and depression during IFN-beta-1a therapy for multiple sclerosis: a case report. Clin Neuropharmacol 2003; 26: 5-7.
11. Pandya R, Patten S. Depression in multiple sclerosis associated with interferon beta-1a. Can J Psychiatry 2002; 47 686.
12. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
13. SPECTRIMS Study Group, Hughes RAC. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496-504.
14. Patten SB, Metz LM. Interferon β-1a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Mult Scler 2001; 7: 243-48.
15. Patten SB, Metz LM. Interferon β 1a and depression in secondary progressive MS. Data from the SPECTRIMS Trial. Neurology 2002; 59: 744-46.
16. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernández O et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study, Lancet 2001; 357: 1576-82.
17. Once Weekly Interferon for MS Study Group. Evidence of interferon B-1a dose response in relapsing-remitting MS. Neurology 1999; 53: 679-86.
18. Andersen O, Elovaara I, Farkkila M, Hansen HJ, Mellgren SI, Myhr KM et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2004; 75: 706-10.
19. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P et al. Randomized, comparative study of interferon β-1a treatment regimens in MS. The EVIDENCE trial. Neurology 2002; 59 1496-506.
20. PRISMS Study Group, University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001; 56: 1628-36.
21. Kappos L, Stam Moraga M. Long-term tolerability of interferon beta-1a in relapsing-remitting multiple sclerosis: 6-year follow-up of the PRISMS study. Mult Scler 2003; 8: S125.
22. Vial T, Choquet-Kastylevsky G, Liautard J, Descotes J. Endocrine and neurological adverse effects of the therapeutic interferons. Toxicology 2000; 142: 161-72.
23. Valentine AD. Managing the neuropsychiatric adverse effects of interferon treatment. Biodrugs 1999; 11: 229-37.
24. Castéra L, Zigante F, Bastie A, Buffet C, Dhumeaux D, Hardy P. Incidence of interferon alfa-induced depression in patients with chronic hepatitis C. Hepatology 2002; 35: 978-79.
25. Hurlock EC, IV. Interferons: potential roles in affect. Med Hypotheses 2001; 56: 558-66.
26. Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997; 54: 531-33.